The Soft Tissue Sarcoma Market was valued at USD 2.5 billion in 2024 and is projected to reach USD 4.8 billion by 2034, registering a CAGR of 6.9%. This growth trajectory is underpinned by a combination of increasing incidences of soft tissue sarcomas, advancements in treatment modalities, and heightened awareness regarding early diagnosis and treatment options. The rising prevalence of risk...